Form 4: Design Therapeutics Director Heather Berger Granted 19,000 Stock Options

Design Therapeutics, Inc. Director Heather A. Berger was granted 19,000 stock options with an exercise price of $4.01 per share, vesting over 12 months.

Summary

• Heather A. Berger, a Director of Design Therapeutics, Inc. (DSGN), was granted 19,000 stock options.
• The transaction date for the option grant was June 10, 2025.
• Each stock option has an exercise price of $4.01.
• The options are exercisable immediately upon grant and have an expiration date of June 9, 2035.
• The shares underlying the option vest in equal monthly installments over 12 months following June 10, 2025.
• All shares subject to the option will be fully vested by the date of the Company's next annual meeting of stockholders.
• Following this transaction, Ms. Berger directly beneficially owns 19,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates alignment of a director's interests with shareholders through equity compensation, a standard and generally well-regarded practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of equity compensation for directors, reflecting ongoing commitment and participation in the company's governance.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shares, although this is a common aspect of equity compensation plans.

Future Outlook

The stock options granted to Director Heather A. Berger are subject to a vesting schedule, with shares vesting in equal monthly installments over 12 months following June 10, 2025, and fully vesting by the Company's next annual meeting of stockholders. This indicates a forward-looking compensation structure tied to future service.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors like Design Therapeutics, Inc. It serves as a key component of executive and director compensation packages, aiming to align leadership incentives with long-term shareholder value creation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Heather A. Berger, a Director of Design Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise of options, but also benefit from increased alignment of director's interests with company performance.
• Director (Heather A. Berger): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest in equal monthly installments over 12 months following June 10, 2025.
• The options will be fully vested by the date of the Company's next annual meeting of stockholders.

Key Dates

Keywords

Design Therapeutics, DSGN, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule